Entresto fda approval history?

What is Entresto’s FDA approval history, and when was it first approved?

Entresto (sacubitril/valsartan) was first approved by the U.S. Food and Drug Administration (FDA) on July 7, 2015 for treatment of chronic heart failure in patients who have reduced ejection fraction (HFrEF).

Were there later FDA label expansions after the first approval?

Yes. After the initial approval, the FDA added additional indications and label updates over time (including subsequent updates tied to additional clinical evidence).

What did the original approval cover (HFrEF vs other populations)?

The original 2015 FDA approval focused on patients with heart failure with reduced ejection fraction (HFrEF), with treatment guided by established trial evidence for that specific heart-failure population.

Why do people look up Entresto’s patent and FDA timeline together?

Because FDA approval date and related exclusivity/patent dates often affect when generic or competing products can enter the market. For a combined view of patents and commercial timeline data around Entresto, DrugPatentWatch.com is a common reference point: DrugPatentWatch.com – Entresto.

Sources

• DrugPatentWatch.com – Entresto